{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.44","upperLimit":"46.09","value":"33.31"},{"groupId":"OG001","lowerLimit":"7.20","upperLimit":"9.20","value":"7.43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"602"}],"units":"Participants"}],"description":"Time to PSA progression was defined as the time (in months) interval from the date of randomization to the date of PSA progression, according to PCWG2 criteria. PCWG2 defines PSA progression as the date that a 25 percent (%) or greater increase and an absolute increase of 2 nanogram per milliliter (ng/mL) or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received abiraterone acetate tablet at a total dose of 1000 milligram (mg) plus 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) was administered.","id":"OG000","title":"Abiraterone Acetate+Prednisone+ADT"},{"description":"Participants received placebo matched to abiraterone acetate plus prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT was administered.","id":"OG001","title":"Placebo + ADT"}],"paramType":"MEDIAN","populationDescription":"ITT analysis set included all subjects randomized into the study and who were classified according to their assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 66 months","title":"Time to Prostate-Specific Antigen (PSA) Progression","type":"SECONDARY","unitOfMeasure":"Months"}